Key takeaways

  • 4D Molecular Therapeutics (NASDAQ: FDMT) reported a wider adjusted loss of $1.08 per share for Q3 2026, missing the Zacks Consensus Estimate.
  • The company's revenue reached $4.15 million, surpassing both analyst estimates and year-ago figures.
  • 4D Molecular Therapeutics has consistently beaten revenue estimates in three of the past four quarters, though it only surpassed EPS estimates once.

4D Molecular Therapeutics (NASDAQ: FDMT) reports a loss of $1.08 per share for the quarter ended September 2026, compared with an estimated loss of $1.05. Its adjusted loss of $1.08 per share is wider than the year-ago loss of $1.01 and the Zacks Consensus Estimate of a $1.04 loss, as highlighted by Zacks Investment Research.

Revenue is about $4.14 million, compared with an estimate of about $4.13 million. Zacks Investment Research reports revenue of $4.15 million, up from $0.09 million a year earlier and 18.77% above its consensus estimate.

4D Molecular Therapeutics beats consensus revenue estimates in three of the past four quarters, while surpassing earnings-per-share estimates once.

4D Molecular Therapeutics trades at a price-to-earnings ratio of -4.34 and a price-to-sales ratio of 7.28. Its debt-to-equity ratio is 0.11, and its current ratio is 6.15.